KraneShares MSCI All China Health Care Index ETF (KURE)
ETF overview
This exchange-traded fund will allocate at least 80% of its net assets, including any capital acquired through borrowing for investment purposes, to financial instruments that are components of its underlying index or exhibit similar economic characteristics. The reference index is a market capitalization-weighted measure, adjusted for free float, and applies a 10/40 Constraint. Its objective is to gauge the equity market performance of Chinese enterprises within the healthcare sector. This fund does not maintain a diversified portfolio.
Fund facts
- Expense ratio
- 0.79%
- Fund assets
- 114.03M USD (all share classes)
- Issuer
- KraneShares
- Inception date
- Jan 31, 2018
- Number of holdings
- 43
Breakdown
Holdings (43)
| Name | Ticker | Weight |
|---|---|---|
| BEONE MEDICINES LTD-H | 6160.HK | 9.18% |
| INNOVENT BIOLOGICS INC | 1801.HK | 8.32% |
| WUXI BIOLOGICS CAYMAN INC | 2269.HK | 7.60% |
| WUXI APPTEC CO LTD-A | 603259.SS | 5.84% |
| SHENZHEN MINDRAY BIO-MEDIC-A | 300760.SZ | 4.92% |
| JIANGSU HENGRUI PHARMACEUT-A | 600276.SS | 4.80% |
| AKESO INC | 9926.HK | 4.21% |
| SINO BIOPHARMACEUTICAL | 1177.HK | 3.75% |
| CSPC PHARMACEUTICAL GROUP LT | 1093.HK | 3.62% |
| WUXI APPTEC CO LTD-H | 2359.HK | 3.41% |
| and 30 more | ||
Similar ETFs
- Global X China Biotech ETF (HKD)2820.HK · Overlap 53% · Expense ratio 0.68%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
KraneShares MSCI All China Health Care Index ETF (KURE)
- Expense ratio
- 0.79%
- Fund assets
- 114.03M USD (all share classes)
- Issuer
- KraneShares
- Inception date
- Jan 31, 2018
- Number of holdings
- 43
| Name | Ticker | Weight |
|---|---|---|
| BEONE MEDICINES LTD-H | 6160.HK | 9.18% |
| INNOVENT BIOLOGICS INC | 1801.HK | 8.32% |
| WUXI BIOLOGICS CAYMAN INC | 2269.HK | 7.60% |
| WUXI APPTEC CO LTD-A | 603259.SS | 5.84% |
| SHENZHEN MINDRAY BIO-MEDIC-A | 300760.SZ | 4.92% |
| JIANGSU HENGRUI PHARMACEUT-A | 600276.SS | 4.80% |
| AKESO INC | 9926.HK | 4.21% |
| SINO BIOPHARMACEUTICAL | 1177.HK | 3.75% |
| CSPC PHARMACEUTICAL GROUP LT | 1093.HK | 3.62% |
| WUXI APPTEC CO LTD-H | 2359.HK | 3.41% |
| and 30 more | ||
This exchange-traded fund will allocate at least 80% of its net assets, including any capital acquired through borrowing for investment purposes, to financial instruments that are components of its underlying index or exhibit similar economic characteristics. The reference index is a market capitalization-weighted measure, adjusted for free float, and applies a 10/40 Constraint. Its objective is to gauge the equity market performance of Chinese enterprises within the healthcare sector. This fund does not maintain a diversified portfolio.
- Global X China Biotech ETF (HKD)2820.HK · Overlap 53% · Expense ratio 0.68%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free